https://pharminent.com/odyssey-eyes-236m-for-renewed-nasdaq-bid-seaport-docks-on-nasdaq/ 2026-05-04T17:15:50Z Pharminent en Odyssey eyes $236M for renewed Nasdaq bid, Seaport docks on Nasdaq 2026-05-04T17:15:50Z Blog https://pharminent.com/223-an-interview-with-dr-antn-blatnik-on-the-molecular-mechanisms-driving-neuromuscular-disease/ 2026-05-04T17:15:52Z Pharminent en 223: An Interview With Dr. Antn Blatnik on the Molecular Mechanisms Driving Neuromuscular Disease 2026-05-04T14:57:02Z Blog https://pharminent.com/eli-lilly-to-acquire-kelonia-therapeutics/ 2026-05-04T17:15:54Z Pharminent en Eli Lilly to Acquire Kelonia Therapeutics 2026-05-04T14:30:19Z Blog https://pharminent.com/gene-therapys-evidence-problem-lessons-from-recent-fda-decisions/ 2026-05-04T17:15:55Z Pharminent en Gene therapy's evidence problem--lessons from recent FDA decisions 2026-05-04T13:23:03Z Blog https://pharminent.com/pci-adds-us-sterile-fill-finish-capabilities-through-1b-global-expansion-drive/ 2026-05-04T17:15:56Z Pharminent en PCI adds US sterile fill/finish capabilities through $1B global expansion drive 2026-05-04T12:57:47Z Blog https://pharminent.com/first-fda-odac-meeting-without-pazdur-highlights-conceptual-challenges-with-trial/ 2026-05-04T17:15:57Z Pharminent en First FDA ODAC meeting without Pazdur highlights conceptual challenges with trial 2026-05-04T12:07:00Z Blog https://pharminent.com/summit-shares-descend-as-pd-1-vegf-asset-misses-early-survival-mark/ 2026-05-04T17:15:57Z Pharminent en Summit shares descend as PD-1/VEGF asset misses early survival mark 2026-05-04T11:29:05Z Blog https://pharminent.com/ucb-to-acquire-candid-in-2-2b-bet-on-bispecifics-for-autoimmune-diseases/ 2026-05-04T17:15:58Z Pharminent en UCB to acquire Candid in $2.2B bet on bispecifics for autoimmune diseases 2026-05-04T10:20:00Z Blog https://pharminent.com/novo-nordisk-to-launch-ozempic-for-type-2-diabetes-in-us-2/ 2026-05-04T17:15:58Z Pharminent en Novo Nordisk to launch Ozempic for type 2 diabetes in US 2026-05-04T08:16:55Z Blog https://pharminent.com/pfizer-arvinas-join-serd-club-with-veppanu-approval/ 2026-05-04T17:15:59Z Pharminent en Pfizer, Arvinas join SERD club with Veppanu approval 2026-05-04T07:33:34Z Blog https://pharminent.com/week-in-review/week-in-review-intelligence-brief-may-2-2026/ 2026-05-02T19:15:39Z Pharminent en Week in Review • INTELLIGENCE BRIEF • May 2, 2026 2026-05-02T19:15:35Z Blog